The paradigm of response in Hodgkin lymphoma (HL) was developed in cytotoxic
chemotherapies and its use as a reference model for immune-modulatory regimens, which …

Glioblastoma multiforme is the most frequent primary brain tumor. The clinical course of
glioblastoma is almost invariably fatal. Combined chemo-irradiation with temozolomide is …

The programmed death-1 (PD-1) regulatory pathway is active in several tumors and a potent
immunotherapeutic target with PD-1 inhibitors. Nivolumab is an anti-PD-1 monoclonal …

Purpose/Objective (s) Standard of care treatment for patients with relapsed and refractory
classic Hodgkin lymphoma (RRHL) involves second line therapy followed by high dose …

The purpose of this study was to assess efficacy and tolerance of anti-programmed death
(PD)-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily …

Central nervous system (CNS) involvement in Hodgkin lymphoma (HL) is exceedingly rare.
Retrospective data from the German Hodgkin Study Group and an international multicenter …

The immunotherapeutic contribution to allogeneic stem cell transplantation's (SCT's)
curative potential in hematological diseases is well recognized, with alloreactive donor T …

Background: Failure of anti-PD1 checkpoint blockade in relapsed or refractory Hodgkin
lymphoma (r/r HL) constitutes an unmet medical need. It has been postulated that anti-PD1 …

Abstract The programmed death-1 (PD-1) pathway of immune evasion is exploited by many
malignancies to limit host T-cell-mediated immune responses. Nivolumab is a PD-1-blocking …